Germany-based pharmaceutical major Boehringer Ingelheim has entered into a collaboration agreement with the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard. The joint project aims to address the urgent and unmet needs of individuals living with mental health conditions, with a specific focus on developing first-in-class treatments for sleep disturbances associated with cognitive impairments in conditions such as schizophrenia and mood disorders.
Financial Terms and Milestone Payments
Under the terms of this partnership, the Broad Institute will receive not only research funding but also an upfront payment. Additionally, there are potential development, regulatory, and sales milestone payments that could reach up to USD 126.5 million. This financial arrangement is complemented by tiered royalties on future product sales of Boehringer Ingelheim.- Flcube.com
